SEC Form 20-F filed by ImmunoPrecise Antibodies Ltd.
$IPA
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2022 | $9.00 | Buy | H.C. Wainwright |
| 10/25/2021 | $12.00 | Buy | Benchmark |
| 10/25/2021 | $12.00 | Buy | The Benchmark Company |
6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a biotherapeutics company delivering advanced solutions in biologics and drug discovery, today announced the successful sale of its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe"), to AVS Bio for a total enterprise value of $12 million USD. AVS Bio, a portfolio company of Arlington Capital Partners, is a leading global provider of critical inputs and services for the bioprocessing and biologics industries. The transaction generated $11.7 million USD in net proceeds on a cash-free, debt-free basis. This transaction marks a meaningful step in IPA's strategic refinement—streamlining its o
Arlington Capital Partners ("Arlington"), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced that its portfolio company AVS Bio, a leading global provider of critical inputs and services for the bioprocessing and biologics industries, acquired ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe" or the "Company"). IPA Europe is a carve-out of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), a biotherapeutics company leveraging proprietary technologies, including its LENSai™ platform, to accelerate the discovery of next-generation biologics. The acquisition expands AVS Bio's European footprint and adds advanced capabilities in antibody
ImmunoPrecise Antibodies Ltd. ("IPA", "Company", "we" or "us") (NASDAQ:IPA), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announces its financial results for the fiscal year ended April 30, 2025. All numbers are expressed in Canadian dollars unless otherwise noted. Financial Highlights: Achieved strong revenue for Fiscal Year 2025 of $24.5 million Delivered highest-ever fourth quarter revenue of $7.0 million Reported record fourth quarter Adjusted EBITDA of ($0.3) million, reflecting improved operating efficiency Achieved fourth quarter gross margin of 64%, up from 48% from Q4 FY24 BioStrand segment grew over 180
SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)
SC 13G/A - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)
SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)
H.C. Wainwright initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $9.00
Benchmark initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00
The Benchmark Company initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00
ImmunoPrecise Antibodies Ltd. ("IPA", "Company", "we" or "us") (NASDAQ:IPA), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announces its financial results for the fiscal year ended April 30, 2025. All numbers are expressed in Canadian dollars unless otherwise noted. Financial Highlights: Achieved strong revenue for Fiscal Year 2025 of $24.5 million Delivered highest-ever fourth quarter revenue of $7.0 million Reported record fourth quarter Adjusted EBITDA of ($0.3) million, reflecting improved operating efficiency Achieved fourth quarter gross margin of 64%, up from 48% from Q4 FY24 BioStrand segment grew over 180
The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and full fiscal year end 2025, on Tuesday, July 29, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live confere
Secures $8-$10M Strategic Partnership Scales AI Infrastructure Collaborations with Vultr and Leading Providers of Advanced GPU technologies to Accelerate de novo Drug Discovery. Unlocking Margin Expansion Through Scalable AI IPA Strengthens Board & Management Team Kamil Isaev, Joseph Scheffler, and Dr. Li Hui join IPA, enhancing leadership in AI, finance, and client relations. IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the third quarter ("Q3") of its 2025 fiscal year ("FY25"), which ended January 31, 2025. "As we continue to revolutionize the AI-enabled drug disc
Arlington Capital Partners ("Arlington"), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced that its portfolio company AVS Bio, a leading global provider of critical inputs and services for the bioprocessing and biologics industries, acquired ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe" or the "Company"). IPA Europe is a carve-out of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), a biotherapeutics company leveraging proprietary technologies, including its LENSai™ platform, to accelerate the discovery of next-generation biologics. The acquisition expands AVS Bio's European footprint and adds advanced capabilities in antibody
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced the appointment of Jeff Fried to its Advisory Board. A recognized leader in healthcare data infrastructure and AI innovation, Jeff Fried brings more than 25 years of experience designing and delivering high-performance data for complex life sciences and clinical environments. He currently serves as Director of Platform Strategy and Innovations for InterSystems, where he helps shape high-performance data solutions for some of the world's most demanding healthcare and life sciences environments. He has serve
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately. Mr. Lieber brings over 30 years of financial and strategic leadership across the biotechnology and life sciences sectors, with deep expertise in capital markets, investor relations, and corporate development. He currently serves as Chief Financial Officer at Rallybio, a clinical-stage biotechnology company developing therapies for severe and rare diseases. He also brings valuable experience in Nasdaq governance, having served as both a senior executive and board member of publicly traded